DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Price, Quote, News and Overview

What is the stock price of DECIPHERA PHARMACEUTICALS IN today?

The current stock price of DCPH is 25.59 USD. The price increased by 0.08% in the last trading session.

What is the ticker symbol for DECIPHERA PHARMACEUTICALS IN stock?

The exchange symbol of DECIPHERA PHARMACEUTICALS IN is DCPH and it is listed on the Nasdaq exchange.

On which exchange is DCPH stock listed?

DCPH stock is listed on the Nasdaq exchange.

What is the price forecast or stock price prediction for DECIPHERA PHARMACEUTICALS IN stock?

16 analysts have analysed DCPH and the average price target is 27.25 USD. This implies a price increase of 6.47% is expected in the next year compared to the current price of 25.59. Check the DECIPHERA PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.

What is DECIPHERA PHARMACEUTICALS IN worth?

DECIPHERA PHARMACEUTICALS IN (DCPH) has a market capitalization of 2.21B USD. This makes DCPH a Mid Cap stock.

How many employees does DECIPHERA PHARMACEUTICALS IN have?

DECIPHERA PHARMACEUTICALS IN (DCPH) currently has 300 employees.

What are the support and resistance levels for DECIPHERA PHARMACEUTICALS IN (DCPH) stock?

DECIPHERA PHARMACEUTICALS IN (DCPH) has a support level at 25.55 and a resistance level at 25.6. Check the full technical report for a detailed analysis of DCPH support and resistance levels.

Is DECIPHERA PHARMACEUTICALS IN (DCPH) expected to grow?

The Revenue of DECIPHERA PHARMACEUTICALS IN (DCPH) is expected to grow by 25.31% in the next year. Check the estimates tab for more information on the DCPH EPS, Sales, EBIT and EBITDA future analyst estimates.

Should I buy DECIPHERA PHARMACEUTICALS IN (DCPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:

• The Technical Analysis (TA) tab contains a technical analysis of DCPH, looking at technical quality and support and resistance levels
• The Fundamental Analysis (FA) tab contains a fundamental analysis of DCPH, evaluating the profitability, health, valuation and growth aspects
• DECIPHERA PHARMACEUTICALS IN (DCPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
• DECIPHERA PHARMACEUTICALS IN (DCPH) Sales and EPS estimates to see what analysts future expectations are.
• DECIPHERA PHARMACEUTICALS IN (DCPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
• DECIPHERA PHARMACEUTICALS IN (DCPH) Insider and Institutional Ownership to learn about the owners and their transactions.
• DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Chart to make your own analysis
• DECIPHERA PHARMACEUTICALS IN (DCPH) Latest news and press-releases to stay up to date.

Does DECIPHERA PHARMACEUTICALS IN (DCPH) stock pay dividends?

DCPH does not pay a dividend.

When does DECIPHERA PHARMACEUTICALS IN (DCPH) report earnings?

DECIPHERA PHARMACEUTICALS IN (DCPH) will report earnings on 2024-08-07, before the market open.

What is the Price/Earnings (PE) ratio of DECIPHERA PHARMACEUTICALS IN (DCPH)?

DECIPHERA PHARMACEUTICALS IN (DCPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.21).

ChartMill assigns a fundamental rating of 4 / 10 to DCPH. No worries on liquidiy or solvency for DCPH as it has an excellent financial health rating, but there are worries on the profitability.

Over the last trailing twelve months DCPH reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS increased by 5.96% compared to the year before.

ChartMill assigns a Buy % Consensus number of 71% to DCPH. The Buy consensus is the average rating of analysts ratings from 16 analysts.

For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 25.31% for DCPH